Zhifei Biological Products secures patent for vaccine-related technology

Chongqing Zhifei Biological Products Co., Ltd., along with its wholly-owned subsidiaries Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. and Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd., announced the acquisition of an invention patent certificate. The patent, titled "CpG oligonucleotide, its adjuvant, vaccine and application," was issued by the National Intellectual Property Administration.

The patent number is ZL202311196410.3. The patent application date was September 15, 2023, and the authorization announcement date is November 28, 2025. The patent holders are Zhifei Biological Products, Zhifei Green Bamboo, and Zhifei Longcom.

The company stated that this invention patent, developed through its independent research and development process, will be applied to relevant R&D projects in the future. The acquisition of this patent certificate is not expected to have a significant impact on the company's recent production and operations. However, it is beneficial for further improving the company's intellectual property protection system, fully leveraging its independent intellectual property advantages, promoting technological innovation, and enhancing the company's core competitiveness.

Chongqing Zhifei Biological Products Co., Ltd. Board of Directors November 28, 2025